MedImmune - Astra Zeneca

Gaithersburg, Maryland

MedImmune is the biologics and biotechnology research and development (R&D) arm of the pharmaceutical and biopharmaceutical manufacturer, AstraZeneca. MedImmune is the mind behind many popular pharmaceutical products on the market today. In 2014, Medimmune’s campus qualified for a Silver Superior Energy Performance® (SEP) award, a certification for industrial facilities based off ISO50001’s global energy management system standards.

With a goal of reducing the carbon footprint, decreasing facility operational costs, increasing power reliability and increasing resiliency against outages, MedImmune contracted with CMTA to design a combined heat and power (CHP) system. This system includes five megawatts of natural gas powered generation capacity, steam and hot water heat recovery heat exchangers and a 500-ton double-effect absorption chiller. However, before connecting the CHP system to the existing campus-wide energy infrastructure, eight different utility electrical services feeding into adjacent campus buildings were consolidated onto a single campus-wide medium voltage switchgear with two new redundant utility feeders. A paralleling switchgear was added to tie together two existing 3 megawatt diesel generators to the CHP systems. This allows the MedImmune campus to respond quickly to an immediate outage, as well as sustain long-term generation during a prolonged outage event by transitioning to island mode.

On an annual basis, the system is designed to offset approximately $1.6 million in operating costs by producing over 32,000 MWH of electricity and 80,000 MMBtu of recovered heat.